Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer

Gene

Volumn 534, Issue 1, 2014, Pages 60-65

  Yu, Hong ^a   Jiang, Lin ^a   Sun, Canlin ^a   Guo, Lingchuan ^b   Lin, Mei ^a   Huang, Junxing ^a   Zhu, Li ^a  

^a TAIZHOU PEOPLE S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Lung cancer; Metastasis; MiR 20a; MiR 31; MiR 375; Survival

Indexed keywords

MICRORNA 20A; MICRORNA 31; MICRORNA 375;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRECANCER; PRIORITY JOURNAL; SURVIVAL RATE;

AGED; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COHORT STUDIES; DOWN-REGULATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED;

EID: 84888035824     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.10.024     Document Type: Article

References (46)

1. Bierkens M., et al. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer 2013, 52:56-68.
2. Bryant R.J., et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106:768-774.
3. Chai H., et al. ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. Int. J. Clin. Exp. Med. 2012, 5:186-194.
4. Chang C., et al. Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma. Neurosci. Lett. 2012, 531:204-208.
5. Chen Q., et al. Prognostic significance of serum miR-17-5p in lung cancer. Med. Oncol. 2013, 30:353.
6. Chow T.F., et al. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J. Urol. 2010, 183:743-751.
7. Dacic S., Kelly L., Shuai Y., Nikiforova M.N. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod. Pathol. 2010, 23:1577-1582.
8. de Souza Rocha Simonini P., et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010, 70:9175-9184.
9. Fan X., et al. miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42:318-324.
10. Harris T., et al. Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am. J. Pathol. 2012, 180:917-928.
11. Hudson J., et al. Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp. Mol. Pathol. 2013, 95:62-67.
12. Isozaki Y., et al. Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. Int. J. Oncol. 2012, 41:985-994.
13. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
14. Jonsdottir K., et al. Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One 2012, 7:e48692.
15. Jung H.M., et al. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interaction. Mol. Biol. Cell 2013, 24:1638-1648.
16. Karakatsanis A., Papaconstantinou I., Gazouli M., Lyberopoulou A., Polymeneas G., Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol. Carcinog. 2013, 52:297-303.
17. Komatsu S., et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br. J. Cancer 2011, 105:104-111.
18. Komatsu S., et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert. Opin. Biol. Ther. 2012, 12(Suppl. 1):S53-S59.
19. Kong K.L., et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61:33-42.
20. Landi M.T., et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 2010, 16:430-441.
21. Leidner R.S., et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012, 51:473-479.
22. Li L.M., et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010, 70:9798-9807.
23. Li Y., Jiang Q., Xia N., Yang H., Hu C. Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J. Int. Med. Res. 2012, 40:1662-1669.
24. Li J., et al. Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One 2013, 8:e53582.
25. Lin Q., et al. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J. Surg. Oncol. 2013, 107:767-771.
26. Liu X., et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest. 2010, 120:1298-1309.
27. Madhavan D., et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 2012, 18:5972-5982.
28. Matsubara H., et al. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene 2007, 26:6099-6105.
29. Meng W., et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in lung adenocarcinoma patients. Clin. Cancer Res. 2013, 10.1158/1078-0432.CCR-13-0320.
30. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
31. Munker R., Calin G.A. MicroRNA profiling in cancer. Clin. Sci. (Lond.) 2011, 121:141-158.
32. Nguyen H.C., et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 2013, 73:346-354.
33. Nishikawa E., et al. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res. 2011, 71:6165-6173.
34. Raponi M., et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009, 69:5776-5783.
35. Sanfiorenzo C., et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One 2013, 8:e54596.
36. Shao X., et al. Mir-375 enhances ruthenium-derived compound Rawq01 induced cell death in human ovarian cancer. Int. J. Clin. Exp. Pathol. 2013, 6:1095-1102.
37. Siegel R., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62:220-241.
38. Sumazin P., et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011, 147:370-381.
39. Szczyrba J., et al. Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol. Cancer Res. 2011, 9:791-800.
40. Tan X., et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin. Cancer Res. 2011, 17:6802-6811.
41. Wang M., et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol. Med. Rep. 2012, 5:1514-1520.
42. Wang S., et al. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin. Transl. Oncol. 2013, 10.1007/s12094-013-1014-4.
43. Wang Y., et al. miR-375 regulates rat alveolar epithelial cell trans-differentiation by inhibiting Wnt/beta-catenin pathway. Nucleic Acids Res. 2013, 41:3833-3844.
44. Wei J., et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin. J. Cancer 2011, 30:407-414.
45. Zhang X., et al. Polymorphisms on 8q24 are associated with lung cancer risk and survival in Han Chinese. PLoS One 2012, 7:e41930.
46. Zhao H., Zhu L., Jin Y., Ji H., Yan X., Zhu X. miR-375 is highly expressed and possibly transactivated by achaete-scute complex homolog 1 in small-cell lung cancer cells. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:177-182.